{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:09:43Z","timestamp":1788548983283,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie agreement","award":["813409"],"award-info":[{"award-number":["813409"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral artery disease (PAD) patients have an increased cardiovascular risk despite pharmacological treatment strategies. Biomarker research improving risk stratification only focused on known atherothrombotic pathways, but unexplored pathways might play more important roles. To explore the association between a broad cardiovascular biomarker set and cardiovascular risk in PAD. 120 PAD outpatients were enrolled in this observational cohort study. Patients were followed for one year in which the composite endpoint (myocardial infarction, coronary revascularization, stroke, acute limb ischemia and mortality) was assessed. Patient data and blood samples were collected upon inclusion, and citrated platelet-poor plasma was used to analyze 184 biomarkers in Olink Cardiovascular panel II and III using a proximity extension assay. Fifteen patients reached the composite endpoint. These patients had more prior strokes and higher serum creatinine levels. Multivariate analysis revealed increased plasma levels of protease-activated receptor 1 (PAR1), galectin-9 (Gal-9), tumor necrosis factor receptor superfamily member 11A (TNFRSF11A) and interleukin 6 (IL-6) to be most predictive for cardiovascular events and mortality. Positive regulation of acute inflammatory responses and leukocyte chemotaxis were identified as involved biological processes. This study identified IL-6, PAR1, Gal-9, TNFRSF11A as potent predictors for cardiovascular events and mortality in PAD, and potential drug development targets.<\/jats:p>","DOI":"10.1038\/s41598-022-23260-3","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:03:06Z","timestamp":1667300586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease"],"prefix":"10.1038","volume":"12","author":[{"given":"B. M. M.","family":"Kremers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Posma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heitmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Glunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pallares Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. C.","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"ten Cate-Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M. E.","family":"Mees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M. H.","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"23260_CR1","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts, M. J. et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur. Heart J. 30, 2318\u20132326 (2009).","journal-title":"Eur. Heart J."},{"key":"23260_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"DL Bhatt","year":"2006","unstructured":"Bhatt, D. L. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295, 180\u2013189 (2006).","journal-title":"JAMA"},{"key":"23260_CR3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","volume":"128","author":"AW Aday","year":"2021","unstructured":"Aday, A. W. & Matsushita, K. Epidemiology of peripheral artery disease and polyvascular disease. Circ. Res. 128, 1818\u20131832 (2021).","journal-title":"Circ. Res."},{"key":"23260_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1161\/ATVBAHA.120.314774","volume":"40","author":"B Kremers","year":"2020","unstructured":"Kremers, B. et al. Plasma biomarkers to predict cardiovascular outcome in patients with peripheral artery disease: A systematic review and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 40, 2018\u20132032 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"23260_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1161\/CIRCULATIONAHA.118.038312","volume":"139","author":"DD Berg","year":"2019","unstructured":"Berg, D. D. et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation 139, 760\u2013771 (2019).","journal-title":"Circulation"},{"key":"23260_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich, P. C., Castell, J. V. & Andus, T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621\u2013636 (1990).","journal-title":"Biochem. J."},{"key":"23260_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1074-7613(00)80334-9","volume":"6","author":"M Romano","year":"1997","unstructured":"Romano, M. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6, 315\u2013325 (1997).","journal-title":"Immunity"},{"key":"23260_CR8","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","volume":"17","author":"FJ Neumann","year":"1997","unstructured":"Neumann, F. J. et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. 17, 3399\u20133405 (1997).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"23260_CR9","first-page":"H1713","volume":"260","author":"U Ikeda","year":"1991","unstructured":"Ikeda, U. et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol. 260, H1713\u2013H1717 (1991).","journal-title":"Am. J. Physiol."},{"key":"23260_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1050-1738(01)00157-8","volume":"12","author":"NL Tsakadze","year":"2002","unstructured":"Tsakadze, N. L., Zhao, Z. & D\u2019Souza, S. E. Interactions of intercellular adhesion molecule-1 with fibrinogen. Trends Cardiovasc. Med. 12, 101\u2013108 (2002).","journal-title":"Trends Cardiovasc. Med."},{"key":"23260_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ajh.2830480205","volume":"48","author":"L Oleksowicz","year":"1995","unstructured":"Oleksowicz, L., Mrowiec, Z., Isaacs, R., Dutcher, J. P. & Puszkin, E. Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation. Am. J. Hematol. 48, 92\u201399 (1995).","journal-title":"Am. J. Hematol."},{"key":"23260_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.104.513085","volume":"112","author":"I Tzoulaki","year":"2005","unstructured":"Tzoulaki, I. et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112, 976\u2013983 (2005).","journal-title":"Circulation"},{"key":"23260_CR13","doi-asserted-by":"publisher","first-page":"661779","DOI":"10.3389\/fneur.2021.661779","volume":"12","author":"Y Tian","year":"2021","unstructured":"Tian, Y. et al. Association of polyvascular disease and elevated interleukin-6 with outcomes in acute ischemic stroke or transient ischemic attack. Front. Neurol. 12, 661779 (2021).","journal-title":"Front. Neurol."},{"key":"23260_CR14","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1242\/dev.126516","volume":"143","author":"IJ McGough","year":"2016","unstructured":"McGough, I. J. & Vincent, J.-P. Exosomes in developmental signalling. Development 143, 2482\u20132493 (2016).","journal-title":"Development"},{"key":"23260_CR15","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1021\/bi700597p","volume":"46","author":"MT Nieman","year":"2007","unstructured":"Nieman, M. T. & Schmaier, A. H. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 46, 8603\u20138610 (2007).","journal-title":"Biochemistry"},{"key":"23260_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1074\/jbc.M113.528273","volume":"289","author":"B Chen","year":"2014","unstructured":"Chen, B., Siderovski, D. P., Neubig, R. R., Lawson, M. A. & Trejo, J. Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins. J. Biol. Chem. 289, 1580\u20131591 (2014).","journal-title":"J. Biol. Chem."},{"key":"23260_CR17","doi-asserted-by":"publisher","first-page":"e0171427","DOI":"10.1371\/journal.pone.0171427","volume":"12","author":"JM Florence","year":"2017","unstructured":"Florence, J. M., Krupa, A., Booshehri, L. M., Allen, T. C. & Kurdowska, A. K. Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1. PLoS ONE 12, e0171427 (2017).","journal-title":"PLoS ONE"},{"key":"23260_CR18","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.2174\/1381612820666140522115801","volume":"20","author":"J Lin","year":"2014","unstructured":"Lin, J., Kakkar, V. & Lu, X. Impact of MCP-1 in atherosclerosis. Curr. Pharm. Des. 20, 4580\u20134588 (2014).","journal-title":"Curr. Pharm. Des."},{"key":"23260_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/ATVBAHA.118.311655","volume":"39","author":"JJ Posma","year":"2019","unstructured":"Posma, J. J. et al. Roles of coagulation proteases and PARs (protease-activated receptors) in mouse models of inflammatory diseases. Arterioscler. Thromb. Vasc. Biol. 39, 13\u201324 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"23260_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1161\/01.ATV.0000167526.31611.f6","volume":"25","author":"JFW Keuren","year":"2005","unstructured":"Keuren, J. F. W. et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler. Thromb. Vasc. Biol. 25, 1499\u20131505 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"23260_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14161","author":"BMM Kremers","year":"2018","unstructured":"Kremers, B. M. M., Ten Cate, H. & Spronk, H. M. H. Pleiotropic effects of the hemostatic system. J. Thromb. Haemost. https:\/\/doi.org\/10.1111\/jth.14161 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"23260_CR22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow, D. A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404\u20131413 (2012).","journal-title":"N. Engl. J. Med."},{"key":"23260_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","volume":"5","author":"MC Walsh","year":"2014","unstructured":"Walsh, M. C. & Choi, Y. Biology of the RANKL\u00e2\u20ac\u201cRANK\u00e2\u20ac\u201cOPG system in immunity, bone, and beyond. Front. Immunol. 5, 511 (2014).","journal-title":"Front. Immunol."},{"key":"23260_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/36593","volume":"390","author":"DM Anderson","year":"1997","unstructured":"Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175\u2013179 (1997).","journal-title":"Nature"},{"key":"23260_CR25","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1073\/pnas.0401060101","volume":"101","author":"C Monaco","year":"2004","unstructured":"Monaco, C. et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 101, 5634\u20135639 (2004).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"23260_CR26","doi-asserted-by":"publisher","first-page":"15817","DOI":"10.1074\/jbc.272.25.15817","volume":"272","author":"T Bourcier","year":"1997","unstructured":"Bourcier, T., Sukhova, G. & Libby, P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J. Biol. Chem. 272, 15817\u201315824 (1997).","journal-title":"J. Biol. Chem."},{"key":"23260_CR27","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.3390\/ijms20174185","volume":"20","author":"K Kojok","year":"2019","unstructured":"Kojok, K., El-Kadiry, A.E.-H. & Merhi, Y. Role of NF-\u03baB in platelet function. Int. J. Mol. Sci. 20, 4185 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"23260_CR28","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.4049\/jimmunol.1901114","volume":"204","author":"H-Y Chen","year":"2020","unstructured":"Chen, H.-Y. et al. Intracellular galectin-9 enhances proximal TCR signaling and potentiates autoimmune diseases. J. Immunol. 204, 1158\u20131172 (2020).","journal-title":"J. Immunol."},{"key":"23260_CR29","doi-asserted-by":"publisher","first-page":"e0227069","DOI":"10.1371\/journal.pone.0227069","volume":"15","author":"N Matsuoka","year":"2020","unstructured":"Matsuoka, N. et al. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS ONE 15, e0227069 (2020).","journal-title":"PLoS ONE"},{"key":"23260_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245\u20131252 (2005).","journal-title":"Nat. Immunol."},{"key":"23260_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clim.2012.01.004","volume":"143","author":"S Oomizu","year":"2012","unstructured":"Oomizu, S. et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin. Immunol. 143, 51\u201358 (2012).","journal-title":"Clin. Immunol."},{"key":"23260_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","volume":"127","author":"M Seki","year":"2008","unstructured":"Seki, M. et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 127, 78\u201388 (2008).","journal-title":"Clin. Immunol."},{"key":"23260_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2369-14-23","volume":"14","author":"Y Kurose","year":"2013","unstructured":"Kurose, Y. et al. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol. 14, 23 (2013).","journal-title":"BMC Nephrol."},{"key":"23260_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/ijbs.23082","volume":"14","author":"B Li","year":"2018","unstructured":"Li, B. et al. The metabonomics study of P-selectin glycoprotein ligand-1 (PSGL-1) deficiency inhibiting the progression of atherosclerosis in LDLR-\/- mice. Int. J. Biol. Sci. 14, 36\u201346 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"23260_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.atherosclerosis.2013.12.052","volume":"233","author":"Y Ozaki","year":"2014","unstructured":"Ozaki, Y. et al. Association between P-selectin glycoprotein ligand-1 and pathogenesis in acute coronary syndrome assessed by optical coherence tomography. Atherosclerosis 233, 697\u2013703 (2014).","journal-title":"Atherosclerosis"},{"key":"23260_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41419-019-1736-5","volume":"10","author":"Z Ye","year":"2019","unstructured":"Ye, Z. et al. The P-selectin and PSGL-1 axis accelerates atherosclerosis via activation of dendritic cells by the TLR4 signaling pathway. Cell Death Dis. 10, 507 (2019).","journal-title":"Cell Death Dis."},{"key":"23260_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","volume":"16","author":"RG Jung","year":"2018","unstructured":"Jung, R. G. et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb. J. 16, 12 (2018).","journal-title":"Thromb. J."},{"key":"23260_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7150\/ijms.13800","volume":"13","author":"K Srikanthan","year":"2016","unstructured":"Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J. I. & Sodhi, K. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the west Virginian population. Int. J. Med. Sci. 13, 25\u201338 (2016).","journal-title":"Int. J. Med. Sci."},{"key":"23260_CR39","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","volume":"26","author":"M-C Alessi","year":"2006","unstructured":"Alessi, M.-C. & Juhan-Vague, I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. 26, 2200\u20132207 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"23260_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven, D. J. & B\u00fchlmann, P. Missforest-Non-parametric missing value imputation for mixed-type data. Bioinformatics. 28, 112\u2013118 (2012).","journal-title":"Bioinformatics"},{"key":"23260_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23260-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23260-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T11:14:47Z","timestamp":1667301287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23260-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23260"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23260-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SH and JG are employees of Bayer AG and own stocks in this company. HtC receives consultancy fees from Alveron, Galapagos, Viatris, research support from Bayer AG and owns stocks in Coagulation Profile; all revenues are deposited at CARIM for research purposes. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18388"}}